Active Surveillance – Watchful Waiting for Prostate Cancer

A prostate cancer diagnosis does not always mean treatment needs to begin immediately. For appropriately selected patients with low-risk prostate cancer, active surveillance can safely delay or avoid surgery, radiation and their potential side effects while closely monitoring the cancer for changes that may indicate treatment is needed.

What Is Active Surveillance for Prostate Cancer?

Active surveillance is a structured approach to managing prostate cancer that is unlikely to cause harm if it is carefully monitored. Instead of beginning treatment immediately, your care team follows the cancer over time using prostate-specific antigen (PSA) testing, clinical evaluation, imaging and repeat biopsy when appropriate.

The goal is not simply to delay treatment. Active surveillance allows patients to avoid or postpone treatment-related side effects while preserving the opportunity for curative treatment if testing shows that the cancer is becoming more aggressive or progressing.

Active Surveillance Is Not “Doing Nothing”

Choosing active surveillance means making an informed decision to monitor the cancer rather than immediately treating it. Regular follow-up is an important part of the strategy because changes in PSA, imaging, biopsy findings or other clinical information can help determine whether it remains appropriate to continue surveillance.

Active Surveillance vs. Watchful Waiting

Although the terms are sometimes used interchangeably, active surveillance and watchful waiting have different goals. Active surveillance involves ongoing cancer monitoring with the expectation that curative treatment may be recommended if the cancer shows meaningful signs of progression.

Watchful waiting generally involves less intensive cancer monitoring and may be appropriate when age, overall health, life expectancy or other medical conditions make the potential benefits of curative prostate cancer treatment less likely to outweigh its risks. The focus is typically on maintaining quality of life and treating symptoms if they develop.

Active surveillance and watchful waiting can provide appropriate patients with alternatives to immediate prostate cancer treatment. Careful evaluation and ongoing communication with your urology team can help determine when monitoring remains appropriate and when it may be time to consider treatment. Our goal is not to treat prostate cancer simply because it is present, but to recommend treatment when its potential benefit justifies its risks and effects on quality of life.

Who May Be a Candidate for Active Surveillance?

Active surveillance is commonly recommended for patients with low-risk localized prostate cancer and may also be considered for carefully selected patients with favorable intermediate-risk disease. The decision is individualized because no single test or measurement determines whether active surveillance is appropriate.

Understanding Prostate Cancer Risk

Your care team evaluates several factors to understand how likely the cancer is to grow or spread. These may include the Grade Group and Gleason score, PSA level, clinical stage, the amount of cancer found in biopsy samples, prostate MRI findings and other clinical information.

Grade Group and Gleason Score

The Gleason scoring system describes how prostate cancer cells look under a microscope and is used together with the Grade Group system to help estimate how aggressively the cancer may behave. Gleason score 6 corresponds to Grade Group 1 and generally represents the lowest-grade prostate cancer identified on biopsy, while higher Grade Groups indicate increasingly aggressive disease.

Your Overall Health Matters

Age alone does not determine whether active surveillance is appropriate. Overall health, life expectancy, other medical conditions and personal priorities are considered alongside the characteristics of the prostate cancer when deciding whether immediate treatment, active surveillance or watchful waiting offers the most appropriate balance of benefits and risks.

What Happens During Active Surveillance?

Active surveillance requires ongoing follow-up to determine whether prostate cancer remains unlikely to cause harm without immediate treatment. Your surveillance plan is personalized based on your cancer risk, previous test results, age and overall health, and may change over time as new information becomes available.

When Might Prostate Cancer Treatment Become Necessary?

The purpose of active surveillance is to identify meaningful changes while treatment with curative intent remains an appropriate option. If follow-up testing indicates that the cancer has become more aggressive, increased in extent or otherwise changed enough to alter its risk, your care team may recommend moving from surveillance to active treatment.

A recommendation for treatment does not mean that active surveillance has failed. For some patients, surveillance provides years without surgery or radiation before a change in the cancer makes treatment appropriate. For others, continued monitoring may remain the best approach for many years.

Staying on Active Surveillance

Patients who remain on active surveillance need to continue their recommended follow-up even when they feel well and have no prostate cancer symptoms. Consistent monitoring gives the care team the information needed to recognize important changes while helping avoid treatment that may not provide additional benefit.

Some patients may also find that their own priorities change over time. Concerns about treatment side effects, anxiety associated with continued monitoring, changes in overall health and personal preferences can all be part of an ongoing discussion about whether surveillance remains the right choice.

When Watchful Waiting May Be Appropriate

Watchful waiting may be considered when the risks or burdens of curative prostate cancer treatment are unlikely to provide meaningful benefit because of age, life expectancy, other significant health conditions or the characteristics of the cancer. Unlike active surveillance, watchful waiting generally does not involve the same structured schedule of repeat testing and biopsy intended to identify a window for curative treatment.

The emphasis is instead on quality of life and managing symptoms if they develop. Choosing watchful waiting is an individualized medical decision made after considering the prostate cancer alongside a patient’s overall health and goals of care.

A Multidisciplinary Approach to Prostate Cancer Care

At Providence Saint John’s Health Center, prostate cancer care brings together specialists in urology, urologic oncology, radiation oncology, medical oncology and other disciplines when appropriate. For patients who eventually need treatment, recommendations can be reconsidered using the most current information about the cancer, your overall health and preferrences.

For additional information, please call 310-582-7137 or request an appointment.